Search - tctmd.com

Displaying 161 - 180 of 280

Sort: Relevancy | Date

News Daily News

Meta-analysis Confirms Advantage of New-Generation DES in STEMI

Todd Neale

August 07, 2014

News Daily News

Bioresorbable Scaffold Performs Well, But Thrombosis Raises Concerns

Todd Neale

July 24, 2014

News Daily News

HOST-ASSURE: Promus Element Noninferior to Resolute in All-Comers Population

July 10, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

Presentation EuroPCR 2014

Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial

Presenter: Stephan Windecker

May 22, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

News Conference News EuroPCR 2014

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

Caitlin E. Cox

May 20, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

News Daily News

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Jason Kahn

February 20, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

February 12, 2014

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

Advertisement

Meta-analysis Confirms Advantage of New-Generation DES in STEMI

Bioresorbable Scaffold Performs Well, But Thrombosis Raises Concerns

HOST-ASSURE: Promus Element Noninferior to Resolute in All-Comers Population

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

Stent Malapposition Frequent, But Without Clinical Consequences

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content